Hilary Baker-Jennings represents a variety of clients in a broad range of industries in complex corporate matters. Ms. Baker-Jennings was a summer associate at WilmerHale in 2015.

Prior to joining WilmerHale, Ms. Baker-Jennings was a student advocate at the Harvard Transactional Law Clinic. While there, she advised on matters that included entity formation, contract drafting, corporate governance, and federal and state securities regulations.

Previously, Ms. Baker-Jennings was a legal intern with the MIT Office of the General Counsel where she assisted attorneys with projects in several disciplines, including labor and employment, policy and compliance, litigation and Institute governance.


    • Constellation Pharmaceuticals, a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, in its Series F financing round and $60 million initial public offering.
    • Depository Trust & Clearing Corporationa financial institution that helps markets grow and protect the security of the global financial system, in its investment into the £77.7M Series B financing round of Fnality.  
    • Editas Medicine, Inc., a clinical stage gene editing company, in multiple public offerings as well as general corporate governance and public reporting matters.
    • Flare Therapeutics, a biotechnology company leveraging the power of “switch sites” as druggable regions that hold the control for predictable and profound changes in DNA transcription and gene expression, in its $82 million Series A financing round and $125 million Series B financing.
    • PTC Therapeutics, a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines for patients with rare disorders, in its strategic financing collaboration with Blackstone for up to $1 billion in funding.
    • Rectify Pharmaceuticals, a developer of therapies to treat genetic disorders using small molecule correctors of ABC transporters, in its $96 million Series A financing round.
    • Volastra Therapeutics, a biotechnology company focused on developing novel therapies for patients with metastatic cancers, in its $20 million Series A financing round.
    • Preferred stock financings on behalf of multiple private company technology clients including Jebbit, Inc., Supply, Inc., and Electra Vehicles, Inc.
    • Various financial and investment institutions in numerous private company investments and financings, initial public offerings and follow-on public offerings.


  • Named to Boston Magazine’s inaugural Top Lawyers list in 2021 and 2023 in the area of corporate law. 

Insights & News


  • Education

    • JD, Harvard Law School, 2016

    • BA, English and Medieval Studies, Rice University, 2011

      cum laude with distinction
  • Admissions

    • Massachusetts



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.